Financial Reporting
Page 1 • 3 itemsGain critical insights into global pharma financial reporting, M&A trends, and investment analysis. Drive strategic decisions with expert intelligence.
Regeneron Q1 2026 Earnings: Dupixent Sales Surge 33% to $4.9B, EYLEA HD Shows Strong Growth
Regeneron reports 19% revenue growth to $3.6B in Q1 2026, driven by Dupixent's 33% sales increase to $4.9B and EYLEA HD's 52% growth to $468M.
Edwards Lifesciences Raises 2026 Guidance After Strong Q1 TMTT Sales Hit $173 Million
Edwards Lifesciences reported Q1 2026 TMTT sales of $173M and raised full-year guidance, with constant currency sales growth increased to 9-11%.
Boston Scientific Reports Strong Q1 2026 Results with $5.2 Billion Revenue, 11.6% Growth
Boston Scientific delivered $5.203 billion in Q1 2026 net sales, marking 11.6% reported growth driven by category leadership strategy and global expansion.